Curium acquires Zevacor Molecular

By staff writers

March 3, 2020 -- Nuclear medicine firm Curium Pharma has acquired radiopharmaceutical developer Zevacor Molecular in a deal aimed at strengthening its PET portfolio.

In announcing the acquisition, Curium highlighted Zevacor's market position for the production of strontium-82, which is used for producing rubidium-82 generators for cardiac PET imaging in the U.S. In addition, Zevacor's manufacturing infrastructure complements Curium's strategic plans for future growth, said Curium Group CEO Renaud Dehareng in a statement.

The Zevacor Molecular business will be rebranded under the Curium name, according to the company. The terms of the deal were not disclosed.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking